Clarifying the role of flumonertinib rechallenge in EGFR-mutated non-small cell lung cancer
Haoyu Wang, Chenyue Zhang, Shanshan Du, Haiyong Wang · 2026
Read Clarifying the role of flumonertinib rechallenge in EGFR-mutated non-small cell lung cancer by Haoyu Wang, Chenyue Zhang, Shanshan Du, Haiyong Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13266718.txt.
Description
Haoyu Wang and the team reply to comments on reusing a targeted lung cancer drug after resistance (2026). Flumonertinib treats cancers with EGFR mutations, and salvage options after third-generation drugs fail are limited. The letter clarifies methods in their earlier real-world study. Two bias concerns receive direct answers.
Selection and immortal time bias can affect retrospective line comparisons, the authors concede. Their line comparison was exploratory, not causal. Survival was redefined from treatment start as more clinically relevant than from diagnosis. Small numbers limit subgroup strength. Prospective studies are called for to validate these preliminary observations.
Catalog record
| CREATOR | Haoyu Wang, Chenyue Zhang, Shanshan Du, Haiyong Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 4 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |